Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of sacubitril sodium丨cas 149690-05-1 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
|
Appearance: |
White or off-white powder |
|
Assay: |
98.0%~102.0% (anhydrous substance) |
|
Identification: |
Retention Time: Similar to Reference Substance IR: Similar to Reference Substance This product shows the flame reaction of sodium salt The X-ray diffraction patterns have peaks at 2 theta: 6.2°±0.2°, 19.9°±0.2°, 21.5°±0.2° |
|
Na: |
4.1%~6.5% (anhydrous substance) |
|
Water: |
5.0% max |
Related Substance
|
SX-9-D: |
0.15% max |
|
SX-9-F: |
0.15% max |
|
Single impurity: |
0.10% max |
|
Total impurities: |
1.0% max |
|
Isomer |
|
|
SX-9-A: |
0.15% max |
|
SX-9-B: |
0.15% max |
|
SX-9-C: |
0.15% max |
Isomer
|
SX-9-A: |
0.15% max |
|
SX-9-B: |
0.15% max |
|
SX-9-C: |
0.15% max |
Residual Solvents 1
|
Ethanol: |
0.5% max |
|
Dichloromethane: |
0.06% max |
|
n-Hexane: |
0.029% max |
|
Ethyl acetate: |
0.5% max |
Residual Solvents 2
|
Methyl Tertiary Butyl Ether: |
0.5% max |
|
Isopropyl acetate: |
0.5% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2933990099307 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials. |
|
Condition to Avoid |
|
|
Package |
Overview
Sacubitril Sodium丨CAS 149690-05-1 is the sodium salt form of sacubitril, a prodrug that is metabolized in the body to its active form, LBQ657. It is best known as a component of the combination drug sacubitril/valsartan (brand name Entresto), which is used for treating heart failure.
Sacubitril is a neprilysin inhibitor-it blocks the enzyme neprilysin responsible for degrading natriuretic peptides, thus enhancing their beneficial cardiovascular effects.
Applications
1. Pharmaceutical Use in Heart Failure Management
Sacubitril Sodium is combined with valsartan (an angiotensin receptor blocker) to form Entresto, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI).
Indicated for treatment of chronic heart failure with reduced ejection fraction (HFrEF).
Improves heart function by:
Enhancing natriuretic peptide levels (vasodilation, natriuresis, diuresis).
Reducing cardiac remodeling and fibrosis.
Lowering blood pressure.
Clinical trials show it reduces mortality and hospitalization rates in heart failure patients.
2. Research and Drug Development
Used as a key chemical in studies exploring neprilysin inhibition and cardiovascular pharmacology.
Serves as a reference compound for developing new ARNI drugs or similar cardiovascular agents.
Benefits
Improves clinical outcomes in heart failure patients when combined with valsartan.
Provides a dual mechanism of action (neprilysin inhibition + RAAS blockade).
Helps reduce symptoms and risk of hospitalization.
Represents a significant advancement over traditional heart failure therapies.
Summary
Sacubitril Sodium丨CAS 149690-05-1 is the sodium salt of sacubitril, a neprilysin inhibitor crucial in the treatment of heart failure as part of the combined drug sacubitril/valsartan (Entresto). It improves cardiac outcomes by potentiating natriuretic peptides and is a key molecule in cardiovascular therapeutic research.
